-
-
-
-
-
-
-
AstraZeneca results: Q1 2026
-
-
-
-
-
-
-
CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
-
-
-
-
-
-
-
BBVA USA (BBVA) and Haleon (HLN) Added to Goldman's European Conviction List Director's Cut for January 2026
-
-
-
-
-
-
-
AstraZeneca earnings preview Q3: stronger print expected, focus on US prices, pipeline
-
-
-
-
-
-
-
AstraZeneca (AZN) Tops Q1 EPS by 139c
-
-
-
-
-
-
-
Morgan Stanley Starts AstraZeneca (AZN:LN) (AZN) at Overweight
-
-
-
-
-
-
-
UBS Upgrades AstraZeneca (AZN:LN) (AZN) to Neutral
-
1,217,283 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

